511 related articles for article (PubMed ID: 22651903)
1. Interleukin-6 signaling pathway in targeted therapy for cancer.
Guo Y; Xu F; Lu T; Duan Z; Zhang Z
Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
[TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
5. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
[TBL] [Abstract][Full Text] [Related]
6. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
[TBL] [Abstract][Full Text] [Related]
8. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
10. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
Ataie-Kachoie P; Pourgholami MH; Morris DL
Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Nishimoto N
Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 regulation of prostate cancer cell growth.
Culig Z; Steiner H; Bartsch G; Hobisch A
J Cell Biochem; 2005 Jun; 95(3):497-505. PubMed ID: 15838876
[TBL] [Abstract][Full Text] [Related]
15. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
Trikha M; Corringham R; Klein B; Rossi JF
Clin Cancer Res; 2003 Oct; 9(13):4653-65. PubMed ID: 14581334
[TBL] [Abstract][Full Text] [Related]
16. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
Smith PC; Keller ET
Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
Matsuda T; Junicho A; Yamamoto T; Kishi H; Korkmaz K; Saatcioglu F; Fuse H; Muraguchi A
Biochem Biophys Res Commun; 2001 Apr; 283(1):179-87. PubMed ID: 11322786
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
20. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
